NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?

NovoCure maintains a commercialized revenue base through its proprietary Tumor Treating Fields oncology platform. Omeros is focused on high-potential therapies for rare diseases and maintains a significant partnership with a global pharmaceutical giant.

The Motley Fool • Jun 22, 2026

NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $NVCR--NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm.

Business Wire • Jun 20, 2026

Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?

Amgen delivers robust cash flow and high net margins through its established portfolio of blockbuster medications. NovoCure offers a unique direct-to-patient model for tumor treatment, targeting niche oncology markets with tumor-treating electrical fields.

The Motley Fool • Jun 19, 2026

Novocure's cancer treatment fails to meet late-stage trial goal

Novocure ​said on ‌Thursday ​that ​its cancer ⁠treatment ​for ​newly diagnosed brain ​tumors ​did not ‌meet ⁠the main ​goal ​of ⁠a ​late-stage ​study.

Reuters • Jun 18, 2026

Novocure Tumbles After Cancer-Fighting Medical Device Flops In Brain Cancer

Novocure stock slumped Thursday after the company's wearable medical device failed in patients with a form of brain cancer.

Investors Business Daily • Jun 18, 2026

Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)

Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of chemoradiation. Shares were down more than 18% midday on June 18, 2026.

PRNewsWire • Jun 19, 2026

Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced topline results today from its Phase 3 TRIDENT trial, which evaluated the initiation of Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma (GBM) at the start of chemoradiation (Early Start Arm) compared to initiating TTFields therapy during the subsequent maintenance phase of treatment (Maintenance Start Arm). The trial did not demonstrate a statistically significant improvement in the primary endpoint.

Business Wire • Jun 18, 2026

CEO Sells 34K Shares of Biotech Stock, Valued at $615,000, According to Latest SEC Filing

34,273 common shares were sold for a transaction value of ~$615,000 at around $17.93 per share on June 4, 2026. The transaction reduced direct holdings by 6.94%, leaving 459,520 shares directly held post-sale.

The Motley Fool • Jun 9, 2026

International Markets and NovoCure (NVCR): A Deep Dive for Investors

Review NovoCure's (NVCR) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Zacks Investment Research • May 4, 2026

NovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer Yet

NovoCure Limited has resolved its CMS billing issue, with no material impact on operations or financials. Q1 2026 revenues grew 12% year-over-year to $174.1M; gross margins improved to 78%, and full-year guidance was raised to $690–710M. Optune Pax launch shows promising demand, but sustainability remains uncertain; Optune Lua for lung cancer has disappointed.

Seeking Alpha • May 1, 2026